Asia-Pacific breast cancer market to outstrip $4.75 billion by 2024, says GBI Research

The breast cancer market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is forecast to grow from $2.16 billion in 2017 to $4.75 billion by 2024, at a compound annual growth rate of 11.9%, according to business intelligence provider GBI Research.

The company’s latest report states that this growth will primarily be driven by the expected approval of promising therapies within several distinct patient segments, as well as the growing market uptake of already approved therapies in the APAC markets. Although several branded drugs are expected to go off patent during the forecast period, the impact of this on the market will be offset by the launch of Verzenio, Lynparza, Nerlynx, talazoparib, alpelisib, taselisib, Keytruda, Tecentriq, margetuximab and ipatasertib, and the increasing uptake of the already approved therapies Ibrance, Kadcyla, Perjeta and Kisqali.

Vivek Goswami, Analyst for GBI Research, explains: “Historically, the triple-negative breast cancer (TNBC) patient population has been poorly catered to, and treatment has been largely dependent on traditional chemotherapies. This has been due to the lack of exploitable targets and a genetically heterogeneous disease phenotype. Little competition currently exists in the TNBC market, leaving an area of considerable opportunity for interested newcomers.”

“Significant advances have been made in developing targeted treatment strategies for TNBC in recent years, with a number of new agents poised to enter in this setting. Several of the newcomers which belong to various therapeutic classes, such as PARP inhibitors and PD-1 modulators, are currently being tested in late-stage trials in various subsets of TNBC patients, and key opinion leaders are enthusiastic about the impact of these agents on eligible patient populations.”

The HER2-positive breast cancer pipeline has weakened in recent years with a small number of new agents currently in late-stage clinical development. By comparison, many more agents are in development for the treatment of HER2-negative disease, which represents the vast majority of the overall breast cancer market.

“Due to the availability of well established therapies, entering the HER2-positive breast cancer market is challenging. Companies hoping to be successful are combining their drugs with existing HER2-targeted therapies. Pfizer is a notable example; its Phase III trial in HR-positive/HER2-positive patients is adding Ibrance following induction with the first-line standard of care in the first-line metastatic setting.

Another strategy employed by Puma Biotechnology’s Nerlynx was to enter into a potentially lucrative new treatment setting, the “extended adjuvant” setting for patients with early-stage disease.”

Vivek explains: “The adjuvant and neoadjuvant settings are expected to remain the greatest contributors to sales during the forecast period.”
“In the HER2-negative/HR-positive segment, the sales of Ibrance in the early disease setting are forecast to grow higher than in the first-line metastatic setting. In addition, the uptake of agents such as Lynparza and Keytruda in the early TNBC setting will drive market growth. Furthermore, the HER2-positive market size will primarily be driven by the uptake of the premium-priced therapy Perjeta in the adjuvant setting.”

Information based on the GBI Research report: Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

-ENDS-

ABOUT GBI RESEARCH

GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.